The Journal of antimicrobial chemotherapy · 2025
Efficacy and safety of earlier switching to an oral antibiotic therapy for the treatment of Gram-positive bloodstream infections: a systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tan ZhaoYi, Liang WenXin, Zhang Na, Liang BeiBei, Bai Nan, Cai Yun
Аннотация
BACKGROUND: Infection specialists show considerable variation in practice, with some advocating IV-to-oral switch for Gram-positive bloodstream infections (GP-BSIs). The efficacy and safety of early switching remain unclear.
METHODS: Systematic review of the efficacy of an early switch to oral antimicrobial therapy in patients with GP-BSIs compared with IV therapy, including treatment failure, all-cause mortality, recurrence, hospital readmission rates, length of hospital stay and adverse events (AEs). PubMed, Embase and the Cochrane Library Database were independently searched up to May 2025. ROBINS-I and ROB-2 tools were used.
RESULTS: A total of 27 studies with 6015 patients were included. Although treatment failure in the IV-to-oral group is comparable to that of IV treatment, the 30-day (OR 0.33, 95% CI 0.13, 0.83) and 90-day all-cause mortality (OR 0.59, 95% CI 0.36, 0.97) in patients with GP-BSIs were significantly lower in association with oral switch. Notably, the decline in all-cause mortality rate was more pronounced in the subgroups of S. aureus (OR 0.37, 95% CI 0.26, 0.53), oral conversion time ≥7 days (OR 0.25, 95% CI 0.16, 0.38) and switched to oral non-β-lactam antibiotics (OR 0.58, 95% CI 0.39, 0.86). Moreover, oral switch therapy significantly reduced hospital stay (MD -6.21 days, 95% CI -7.99, -4.43). Recurrence rate, hospital readmission rates and AEs were similar between IV and oral switch groups.
CONCLUSIONS: This meta-analysis, although primarily based on observational studies, supports that transitioning from IV to oral therapy constitutes a suitable alternative for patients with GP-BSIs exclusively managed via parenteral administration.
METHODS: Systematic review of the efficacy of an early switch to oral antimicrobial therapy in patients with GP-BSIs compared with IV therapy, including treatment failure, all-cause mortality, recurrence, hospital readmission rates, length of hospital stay and adverse events (AEs). PubMed, Embase and the Cochrane Library Database were independently searched up to May 2025. ROBINS-I and ROB-2 tools were used.
RESULTS: A total of 27 studies with 6015 patients were included. Although treatment failure in the IV-to-oral group is comparable to that of IV treatment, the 30-day (OR 0.33, 95% CI 0.13, 0.83) and 90-day all-cause mortality (OR 0.59, 95% CI 0.36, 0.97) in patients with GP-BSIs were significantly lower in association with oral switch. Notably, the decline in all-cause mortality rate was more pronounced in the subgroups of S. aureus (OR 0.37, 95% CI 0.26, 0.53), oral conversion time ≥7 days (OR 0.25, 95% CI 0.16, 0.38) and switched to oral non-β-lactam antibiotics (OR 0.58, 95% CI 0.39, 0.86). Moreover, oral switch therapy significantly reduced hospital stay (MD -6.21 days, 95% CI -7.99, -4.43). Recurrence rate, hospital readmission rates and AEs were similar between IV and oral switch groups.
CONCLUSIONS: This meta-analysis, although primarily based on observational studies, supports that transitioning from IV to oral therapy constitutes a suitable alternative for patients with GP-BSIs exclusively managed via parenteral administration.